Guardant Health to Appeal Federal District Court Judgment

Key Terms

intellectual property regulatory

Intellectual property are legal rights that protect creations of the mind—such as inventions, brand names, designs, software, or secret formulas—giving the owner control over who can use, copy or sell them. For investors, IP is like owning a blueprint or recipe: it can generate steady income through exclusive sales or licensing, boost a company’s competitive edge and valuation, and also create costs or risks if rights must be defended or challenged in court.

royalties financial

Payments made to the owner of an asset or intellectual property each time that asset is used or a product is sold, often calculated as a percentage of sales or a set amount per unit. Royalties matter to investors because they create predictable, ongoing income streams and affect a company’s cash flow and valuation—like a landlord collecting rent or an author getting a steady cut whenever a book is sold.

patents regulatory

Patents are government-granted rights that give an inventor exclusive control to make, use, sell or license a specific invention for a limited time, like a temporary lock on a new product or process. For investors, patents matter because they can create a protected revenue stream, raise barriers for competitors, support higher valuations, and also carry risks from expiration or legal challenges.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• Current Guardant Reveal, Shield products excluded from final District Court order
• Company has validated Guardant360 design improvements to exclude impact of potential royalties

PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will appeal the final judgment from the U.S. District Court for the District of Delaware related to intellectual property claims brought against Guardant by TwinStrand Biosciences, Inc. and University of Washington, with execution of the final judgment and collection of potential royalties stayed pending appeal.

“We strongly disagree with this decision and will promptly be appealing for its overturn,” said John Saia, Guardant Health Chief Legal Officer. “We have full faith in the strengths and merits of Guardant’s intellectual property and R&D and are confident we will ultimately prevail on appeal.”

Importantly, the order published on Friday regarding the scope of royalties expressly defined the products included as those that existed at the time of the trial in 2023, many of which have been discontinued or significantly upgraded. Based on Guardant’s updated technology the current versions of Guardant Reveal and Shield are excluded from the order and potential royalties. In addition, the company has validated design improvements to Guardant360 and related services that would exclude impact of the potential ongoing royalties in the decision.

Guardant remains confident that it did not infringe the asserted patents. Both TwinStrand patents have been preliminarily invalidated in the company’s ongoing challenges before the U.S. Patent and Trademark Office. Separately, Guardant is pursuing appeals before the U.S. Court of Appeals for the Federal Circuit.

About Guardant Health

Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.

Guardant Health Forward-Looking Statements

This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health’s liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health’s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2025 and in its other reports filed with or furnished to the Securities and Exchange Commission. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health’s views as of any date subsequent to the date of this press release.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260824854156/en/

Investor Contact:
Zarak Khurshid
investors@guardanthealth.com

Media Contact:
Meaghan Smith
press@guardanthealth.com

Source: Guardant Health, Inc.